about
PR3-ANCA in Wegener's granulomatosis prime human mononuclear cells for enhanced activation via TLRs and NOD1/2Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDLMonitoring with serum SP-A, SP-D, and KL-6 in a patient with interstitial pneumonia complicated with ANCA-associated glomerulonephritis.Culture-negative subacute bacterial endocarditis masquerades as granulomatosis with polyangiitis (Wegener's granulomatosis) involving both the kidney and lungM2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN.Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitisVascular endothelial growth factor may provide additional values to C-reactive protein and anti-myeloperoxidase titer as a parameter for evaluating disease activity in anti-myeloperoxidase associated vasculitis.Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management.Current pharmacotherapy for the treatment of crescentic glomerulonephritis.Antibodies to proteinase 3 prime human oral, lung, and kidney epithelial cells to secrete proinflammatory cytokines upon stimulation with agonists to various Toll-like receptors, NOD1, and NOD2.Anti-proteinase 3 antibodies (c-ANCA) prime CD14-dependent leukocyte activation.Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis.In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase.Antineutrophil cytoplasmic antibodies induce decreased CD62L expression and enhanced metabolic activity in monocytes.Apoptosis-induced proteinase 3 membrane expression is independent from degranulation.
P2860
Q27489023-FD49097C-DD08-4487-95F5-65C792973CD5Q28365433-F6AFC2FC-9E1F-45C1-B809-BD56EA42D370Q33628190-7FE921D3-BFA7-400E-9097-4ABBA167D55DQ34523158-41BF7812-6B2B-4ADB-A3F3-D5CB8498A90DQ34828532-32117230-E7C3-4D24-A915-D8205FDC7DEDQ35549024-A1099CED-71FD-48B2-B6CE-DCBAB825F5AAQ35605669-2DF643AA-A22F-4820-B5E2-16345CB9C185Q36234282-3D3E2516-A0B4-436C-B829-6D676A410563Q36623061-671176CB-F000-45F3-9FC2-DE387B92510BQ39755699-FE21656C-E264-40C1-84FD-829657BC452EQ43887874-7103F73D-C9F7-42B8-AD6C-62FF83F33720Q43924598-9A320CD1-5279-4B2C-BC80-2C4894DD3550Q44068966-966EE0B3-3232-4B96-B0A2-8391F46E7AE8Q44316844-59AD6AFE-9BBA-4B96-8805-6F1F9DE0AD55Q44606560-06000EB1-9BD1-418D-8BBD-1CEBA2244EF6
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pathophysiology of ANCA-associated glomerulonephritis.
@ast
Pathophysiology of ANCA-associated glomerulonephritis.
@en
type
label
Pathophysiology of ANCA-associated glomerulonephritis.
@ast
Pathophysiology of ANCA-associated glomerulonephritis.
@en
prefLabel
Pathophysiology of ANCA-associated glomerulonephritis.
@ast
Pathophysiology of ANCA-associated glomerulonephritis.
@en
P2093
P356
P1476
Pathophysiology of ANCA-associated glomerulonephritis.
@en
P2093
Kallenberg CG
Limburg PC
Muller Kobold AC
Tervaert JW
van der Geld YM
P304
P356
10.1093/NDT/14.6.1366
P407
P577
1999-06-01T00:00:00Z